TD Cowen analyst Ritu Baral has maintained their bullish stance on GHRS stock, giving a Buy rating yesterday.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Ritu Baral has given her Buy rating due to a combination of factors that highlight GH Research’s strategic progress and financial stability. The company is actively engaging with the FDA to resolve a clinical hold related to prior rat histology findings, demonstrating their commitment to advancing their GH001 program. GH Research is leveraging expert consultants to provide a comprehensive response, including new mechanistic arguments and additional preclinical data, which underscores their proactive approach to regulatory challenges.
Moreover, GH Research’s financial health is robust, with a cash balance of $309 million at the end of Q2, providing a cash runway into 2027. This financial stability supports their ongoing research and development efforts, including the finalization of their Phase 3 TRD program design, which is expected to commence in 2026. The company’s strategic planning, including the involvement of a KOL steering committee and ongoing CRO and site selection, further strengthens their position in the market. These factors collectively contribute to Ritu Baral’s positive outlook and Buy rating for GH Research.
In another report released yesterday, Canaccord Genuity also reiterated a Buy rating on the stock with a $35.00 price target.